Prices are updated after-hours


Sort by: after hours percent change | delayed percent change | gain open | gain high | gain close | publishing date

tags : Trial    save search

Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor
Published: 2022-07-01 (Crawled : 18:00) - prnewswire.com
ENDP | News | $0.57 22.4% -5.99% | twitter stocktwits trandingview |
Health Technology
| | O: -0.52% H: 54.73% C: 43.21%
AMRX | News | $3.36 5.66% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 6.29% C: 5.66%

opana trial
WFC CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Wells Fargo (WFC) Investors with Significant Losses to Contact the Firm's Attorneys, Securities Class Action Filed
Published: 2022-07-01 (Crawled : 13:20) - prnewswire.com
WFC | News | $39.92 1.92% 0.2% | twitter stocktwits trandingview |
Finance
| | O: -0.46% H: 3.51% C: 3.1%

trial
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
Published: 2022-06-30 (Crawled : 01:00) - biospace.com/
TAK | News | $14.09 0.36% -1.7% | twitter stocktwits trandingview |
Health Technology
| | O: 0.51% H: 0.0% C: 0.0%

takhzyro children trial positive results
BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2022-06-30 (Crawled : 17:00) - biospace.com/
FNCTF | News | $11.99 | twitter stocktwits trandingview |
Communications
| | O: 1.06% H: 0.0% C: 0.0%
BICX | $2.5 | twitter stocktwits trandingview |
Health Care and Social Assistan...
| | O: 6.44% H: 0.81% C: 0.81%

bicx104 treatment opioid for trial
Angion Ends Kidney Disease Trial while Novo Hits NASH Wall
Published: 2022-06-30 (Crawled : 14:20) - biospace.com/
ANGN | $1.11 -2.63% -1.75% | twitter stocktwits trandingview |
| | O: -32.75% H: 2.61% C: -0.87%

disease kidney trial wall nash
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
Published: 2022-06-30 (Crawled : 12:00) - globenewswire.com
BRTX | $2.9501 5.08% | twitter stocktwits trandingview |
Professional, Scientific, and T...
| | O: 0.58% H: 0.58% C: -14.98%

disease for trial
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Published: 2022-06-30 (Crawled : 12:00) - globenewswire.com
TOMDF | $0.0134 | twitter stocktwits trandingview |
Manufacturing
| | O: 0.0% H: 0.75% C: 0.75%

covid-19 trial tollovir positive biomarkers
Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease
Published: 2022-06-29 (Crawled : 23:00) - biospace.com/
ANGN | $1.11 -2.63% -1.75% | twitter stocktwits trandingview |
| | O: -1.65% H: 0.0% C: -4.47%

ang-3070 disease kidney trial
ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy
Published: 2022-06-29 (Crawled : 22:00) - biospace.com/
CLPT | $12.5 -4.22% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: -1.11% H: 3.59% C: 2.02%

trial therapeutics therapy
89bio Seeks $94.5M for Phase III SHTG Trial
Published: 2022-06-29 (Crawled : 17:00) - biospace.com/
ETNB 3 d | $3.25 0.93% 0.93% | twitter stocktwits trandingview |
Health Technology
| | O: 7.27% H: 4.88% C: -6.5%

for trial
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Generac Holdings (GNRC) Investors with Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations
Published: 2022-06-29 (Crawled : 14:00) - prnewswire.com
GNRC | $217.51 3.29% -0.19% | twitter stocktwits trandingview |
Producer Manufacturing
| | O: 0.79% H: 0.0% C: -1.88%

trial
NOTV ALERT: Hagens Berman, National Trial Attorneys, Encourages Inotiv, Inc. (NOTV) Investors with Significant Losses to Contact the Firm's Attorneys, Securities Fraud Case Filed
Published: 2022-06-29 (Crawled : 14:00) - prnewswire.com
NOTV | News J | $9.81 2.19% 0.0% | twitter stocktwits trandingview |
Manufacturing
| | O: -1.01% H: 2.55% C: -2.65%

trial
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Published: 2022-06-29 (Crawled : 13:20) - biospace.com/
ADXSD new | $3.25 | twitter stocktwits trandingview |
n/a
| | O: 2.15% H: 16.57% C: 8.13%

adxs-504 treatment for trial cancer
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell DiseasePhase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trial
Published: 2022-06-29 (Crawled : 13:20) - biospace.com/
GBT | $32.77 2.57% -1.72% | twitter stocktwits trandingview |
Health Technology
| | O: -0.34% H: 10.15% C: 8.54%

gbt601 for trial
Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer
Published: 2022-06-29 (Crawled : 13:00) - biospace.com/
CDAK | $2.57 -10.76% 2.43% | twitter stocktwits trandingview |
Health Technology
| | O: -5.04% H: 0.0% C: 0.0%

liver trial cancer
Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation
Published: 2022-06-29 (Crawled : 13:00) - biospace.com/
ACHV | $4.99 2.25% 0.21% | twitter stocktwits trandingview |
Health Technology
| | O: -2.9% H: 1.99% C: 1.0%

sciences for life trial
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
Published: 2022-06-29 (Crawled : 12:20) - biospace.com/
ADCT | News | $8.54 7.42% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: -4.93% H: 3.94% C: 2.23%

zynlonta trial therapeutics
Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis
Published: 2022-06-29 (Crawled : 12:20) - biospace.com/
TRVI A | $2.905 3.38% -0.36% | twitter stocktwits trandingview |
Health Technology
| | O: 21.67% H: 12.55% C: -0.81%

treatment trial therapeutics positive results haduvio
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
Published: 2022-06-29 (Crawled : 12:00) - globenewswire.com
GRTX | $1.29 -0.77% 3.85% | twitter stocktwits trandingview |
Health Technology
| | O: -3.9% H: 1.35% C: -10.81%

for trial results phase 1 rucosopasem
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer
Published: 2022-06-29 (Crawled : 11:00) - globenewswire.com
ALRN | $0.2432 -6.46% 1.92% | twitter stocktwits trandingview |
Health Technology
| | O: -12.84% H: 0.0% C: -21.0%

alrn-6924 for trial therapeutics cancer

USA Holiday (Independence Day) in 2 days

Your saved searches
Save your searches and get alerts when important news are released.

Mentioned Today
APPN | News 4 | $47.15 -0.44% 4.22% | twitter stocktwits trandingview |
Technology Services

ARQQ | News | $6.2 -1.74% -2.54% | twitter stocktwits trandingview |
Information

CDNA | News | $22.38 4.19% 0.0% | twitter stocktwits trandingview |
Health Technology

FNCTF | News | $11.99 | twitter stocktwits trandingview |
Communications

HLF | News | $21.56 5.43% 0.0% | twitter stocktwits trandingview |
Distribution Services

HYB | News | $9.16 0% | twitter stocktwits trandingview |
Miscellaneous

NVAX | News 4 | $57.11 11.04% 0.91% | twitter stocktwits trandingview |
Health Technology

OKTA | News 4 | $95.96 6.15% -0.61% | twitter stocktwits trandingview |
Technology Services

OSCR | News | $4.57 7.53% 0.0% | twitter stocktwits trandingview |

PEGA | News | $49.44 3.34% 0.0% | twitter stocktwits trandingview |
Technology Services

PM | News 4 | $99.72 0.99% -0.07% | twitter stocktwits trandingview |
Consumer Non-Durables

TDOC | News | $34.83 4.88% -0.4% | twitter stocktwits trandingview |
Health Services

TILE | News | $12.695 1.24% 0.0% | twitter stocktwits trandingview |
Producer Manufacturing

UL | News | $46.29 1.0% -0.02% | twitter stocktwits trandingview |
Consumer Non-Durables

UNLYF | News | $45.67 | twitter stocktwits trandingview |
Consumer Non-Durables